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Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the ef-
fective regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices. 
Iowa Code §155A.2(1).
Outreach Efforts to Iowa Pharmacists and 
Technicians – Evening Dinner Meetings
The Board is pleased 
to announce that it is ini-
tiating a new program 
to reach out to all Iowa 
pharmacists and technicians. As part of this effort, the Board 
will be holding a series of meetings across the state during 
the last half of 2011. The purpose of the meetings is to engage 
Iowa pharmacists and technicians in meaningful dialogue to 
learn what their concerns are and what they need help with. 
The Board will also use these meetings as an opportunity to 
educate pharmacists and technicians about changes in laws and 
rules, as well as issues that the Board is dealing with. Meet-
ings will be held from 6 pm to 9 pm, beginning with dinner and 
ending with a “townhall” type meeting. The meetings will 
focus on and encourage audience participation. Meetings will 
be held as follows:
 ♦ Tuesday evening, September 13, 2011, at the Blank Park 
Zoo in Des Moines
 ♦ Thursday evening, October 13, 2011, in Council Bluffs
 ♦ Thursday evening, November 10, 2011, in Iowa City 
Meeting venues for Council Bluffs and Iowa City have not 
yet been selected and will depend on the number of persons 
who register to attend the dinner meetings. There will be no 
registration fee. However, reservations are required and at-
tendees need to register at least two weeks prior to the meeting. 
Any pharmacist or technician who wishes to attend one of the 
meetings should send an e-mail to the Board office to Becky 
Hall at rebecca.hall@iowa.gov. E-mails should include the at-
tendee’s full name and address, indicate whether the attendee 
is a pharmacist or a technician¸ and indicate which meeting he 
or she wishes to attend. The Board office will confirm all meet-
ing reservations and provide attendees with detailed meeting 
information. These meetings will be limited to the first 300 
persons who register for each location. The Board will award 
1.5 hours of continuing education (non-ACPE) for this meeting.
Other Outreach Efforts  
In addition to the dinner meetings referred to above, the 
Board will also utilize other outreach methods. Beginning in 
mid-2011, the Board will send electronic opinion surveys to 
Iowa pharmacists on various issues relating to practice issues, 
regulatory issues, and the use of licensing and registration fees 
collected by the Board. The Board will increase the use of its 
Web site and RSS feeds, as well as direct e-mail alerts and 
broadcasts. In addition, the Board will explore innovative ways 
to better communicate with licensees and registrants, includ-
ing the use of various forms of social media such as Facebook, 
Twitter, and Google. The Board believes that improved and 
more frequent communication with the pharmacy community 
will be beneficial to all.
Board Receives National Award  
The Iowa Board of Phar-
macy was awarded the Fred T. 
Mahaffey Award by the National 
Association of Boards of Phar-
macy® (NABP®) at the NABP 106th 
Annual Meeting in Anaheim, CA, 
on May 25, 2010. The Board was 
recognized for its efforts to combat 
the illegal distribution of drugs via 
the Internet and also for its efforts 
to reclassify marijuana as a Schedule II controlled substance. 
Vern Benjamin, RPh, accepted the award on behalf of the 
Board. The award is given for exceptional contributions to 
the protection of the public health and welfare and furthering 
the mission of NABP. The award plaque is now on permanent 
display at the Board office. The Board thanks NABP for this 
prestigious honor.
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laws when collecting SSNs for purposes of internal data verification and 
board of pharmacy licensure processes. In addition, NABP has high 
security protocols and utilizes required technologies and protections, 
including encryption technologies, to protect sensitive information.
Some pharmacists have asked about using the National Provider 
Identifier (NPI) number from the Centers for Medicare & Medicaid 
Services (CMS) as an alternative to providing their SSN. However, 
applying for an NPI number requires candidates to disclose their SSN 
to CMS, and may not address candidate concerns about providing their 
SSN to third parties. In addition, this excludes pharmacy technicians, 
who are not eligible for an NPI number. 
A verification process using the SSN is the best way for organizations 
like NABP to help ensure the accuracy of data within its systems. NABP 
collects and reports data such as examination scores and continuing 
education records to the boards of pharmacy and having incorrect data 
could create serious adverse consequences for licensees. The use of the 
full nine-digit SSN, along with other demographic information such as 
license number(s), will help NABP internally verify that each profile 
created within its systems is unique, contains accurate information, 
and will match state board licensure records. The SSN is not used for 
any other purposes and is not shared with other entities except for the 
purposes of delivering requested services.
Reputable organizations use secure collection, storage, and disposal 
procedures, such as SSL encryption, access restriction and monitoring, 
firewalls, and shredding to protect customers information and thwart 
would-be hackers and identity thieves. Nevertheless, understanding how 
identity thieves steal your information will help you protect yourself from 
identity theft. According to the Social Security Administration thieves 
acquire your personal information by:
 ♦ Stealing wallets, purses, and your mail (bank and credit card state-
ments, pre-approved credit offers, new checks, and tax information); 
 ♦ Stealing personal information you provide to an unsecured site on the 
Internet, from business or personnel records at work, and personal 
information in your home; 
 ♦ Rummaging through your trash, the trash of businesses, and public 
trash dumps for personal data; 
 ♦ Posing by phone or e-mail as someone who legitimately needs infor-
mation about you, such as employers or landlords; or 
 ♦ Buying personal information from “inside” sources. For example, an 
identity thief may pay a store employee for information about you 
that appears on an application for goods, services, or credit. 
Contaminated TPN Spurs ISMP Call for Action
In response to the infections of 19 Alabama patients by contami-
nated total parenteral nutrition (TPN), the Institute for Safe Medication 
Practices (ISMP) called upon Food and Drug Administration (FDA) to 
take several actions, including collaborating with boards of pharmacy 
in enforcing compounding standards. An investigation led by Alabama 
Department of Public Health and Centers for Disease Control and Pre-
vention (CDC) determined that a failure in a step of the sterilization pro-
cess for the compounded TPN most likely led to its contamination with 
Serratia marcescens bacteria. Of the 19 cases of infection that resulted 
in Birmingham, AL, area hospitals, nine were fatal. An investigation 
revealed that TPN produced by Meds IV was the common source of 
the infections and that a container and stirrer, and a tap water spigot at 
Meds IV are likely the sources of the bacteria. The product was recalled 
by Meds IV on March 24, 2011.
ISMP has expressed support for the provision of additional resources 
to boards of pharmacy so that boards can survey compounding pharma-
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Pharmacists Provide Feedback at APhA:  
‘It's About Time! What a Great Tool’
Since the March 2011 launch of the new CPE Monitortm service, more 
than 10,000 pharmacists and technicians have created their National 
Association of Boards of Pharmacy® (NABP®) e-Profile and obtained 
their permanent identification number. In its effort to educate licensees, 
NABP answered questions about CPE Monitor during the American 
Pharmacists Association (APhA) Annual Meeting and Exposition on 
March 25-28, 2011, in Seattle, WA, in which pharmacists shared with 
NABP staff positive feedback about the new service. Visitors to the 
booth noted that they are looking forward to using the new tool to track 
their continuing pharmacy education (CPE). 
Beginning in the latter part of 2011, the CPE Monitor service will 
allow pharmacists and technicians to easily track their Accreditation 
Council for Pharmacy Education (ACPE)-accredited CPE credits. The 
service will also provide a streamlined reporting and compliance veri-
fication process for participating state boards of pharmacy, a capability 
scheduled for availability in 2012. In the latter part of 2011, the e-Profile 
ID and birth date (MMDD) will be required to receive credit for any 
CPE activities taken from ACPE-accredited providers. Providers will 
ask CPE participants to provide the ID either when registering for CPE 
or when submitting participation data to the provider.
Pharmacists whose names have changed since the last time they 
interacted with NABP will need to go through the name change process 
before beginning their CPE Monitor registration. Name changes can be 
made in the licensee’s NABP e-Profile by submitting a photocopy of the 
document granting your name change and completing the correct NABP 
name change form. These downloadable forms are available on the 
NABP Web site at www.nabp.net/programs/cpe-monitor/cpe-monitor-
service in the frequently asked questions section. One form pertains 
to those who have had their name change granted by a United States 
government agency, and the other form pertains to those who have had 
their name change granted by a foreign government agency. In addition 
to the form, licensees must submit a photocopy of the documentation 
noting the name change, which includes marriage license or certificate, 
divorce decree, or court ordered name change document.
Pharmacists and technicians may access additional information 
about CPE Monitor in the Programs section on the NABP Web site at 
www.nabp.net/programs or at www.MyCPEmonitor.net. CPE Monitor 
is a collaborative effort between NABP, ACPE, and ACPE providers.
Protecting Yourself from Identity Theft
Being asked for your Social Security number (SSN) when applying 
for a loan or credit card, or even when setting up an account with a 
business for a service, is now commonplace. With this increased use of 
SSNs comes the increased risk of identity theft, and reputable businesses 
have been diligent in taking measures to implement security protocols 
to protect their customers. 
Although some may believe that non-governmental organizations are 
prohibited from obtaining SSNs, in fact there is no law banning private 
organizations, such as NABP, from collecting this information. In recent 
years, a federal government task force recognized the importance of 
SSN use by private entities and preservation of such use. In addition, 
many states’ laws specifically permit private entities to collect and use 
individual SSNs for purposes of application and enrollment processes, 
to confirm SSN accuracy, or for internal verification or administrative 
purposes. 
For many decades, NABP has supported the boards of pharmacy in 
their licensure processes and the Association adheres to state and federal 
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cies to enforce compliance with United States Pharmacopeia Chapter 
797 standards. ISMP also calls upon FDA to work with state boards of 
pharmacy to support enforcement efforts and to provide guidance docu-
ments for industry on relevant good pharmacy compounding practices. 
More information about ISMP’s call for action is available in an April 
7, 2011 article on the ISMP Web site at www.ismp.org.
ISMP Provides Strategies to Enhance Safety 
Procedures in Pharmacies
This column was prepared by ISMP. ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To read about 
the risk reduction strategies that you can put into practice today, sub-
scribe to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP is a federally certified patient 
safety organization, providing legal protection and confidentiality for 
submitted patient safety data and error reports. ISMP is also an FDA 
MedWatch partner. Call 1-800/FAIL-SAF(E) to report medication errors 
to the ISMP Medication Errors Reporting Program or report online at 
www.ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, 
PA 19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
When investigating errors, look for contributing factors and then ap-
ply prevention recommendations that make sense for your organization. 
Use a variety of the strategies listed below to focus on system issues 
and human factors, to continually enhance safety procedures in your 
pharmacy. Share this information with colleagues at your site and within 
your greater organization.
Fail-safes and constraints involve true system changes in the design 
of products or how individuals interact within the system. For instance, 
when the pharmacy computer system is integrated with the cash register, 
a fail-safe would prevent the clerk from “ringing up” the prescription 
unless final verification by a pharmacist had occurred.
Forcing functions are procedures that create a “hard stop” during a 
process to help ensure that important information is provided before 
proceeding. For example, a pharmacy computer system is integrated 
with the cash register and requires the patient’s date of birth be asked 
and entered at the point of sale.
Automation and computerization of medication-use processes can 
reduce reliance on memory. Examples include true electronic systems 
that can receive electronic prescriptions from a prescriber, thus eliminat-
ing data entry misinterpretation at the pharmacy and robotic dispensing 
devices with bar coding.
Standardization creates a uniform model to adhere to when perform-
ing various functions and to reduce the complexity and variation of a 
specific process. For example, create standardized processes to guide 
the pharmacist’s final verification of a medication. 
Redundancies incorporate duplicate steps or add another individual 
to a process, to force additional checks in the system. Involving two 
individuals in a process reduces the likelihood that both will make the 
same error with the same medication for the same patient. Examples 
include use of both brand and generic names when communicating 
medication information. Patient counseling is often an underutilized 
redundancy that can detect many errors.
Reminders and checklists help make important information readily 
available. For example, prescription blanks that include prompts for 
important information (eg, medication indication, allergies, patient 
birth date).
Rules and policies are useful and necessary in organizations. Effec-
tive rules and policies should guide staff toward an intended positive 
outcome. However, some may add unnecessary complexity and may be 
met with resistance, especially when implemented in haste in response 
to an error. Because their use relies on memory, they should be used as 
a foundation to support other strategies that target system issues.
Education and information are important tactics when combined 
with other strategies that strengthen the medication-use system. The ef-
fectiveness of these tactics relies on an individual’s ability to remember 
what has been presented. Thus, on their own, they offer little leverage 
to prevent errors. An example of an education strategy would be having 
pharmacy personnel read and review policies and procedures on how to 
correctly perform a function such as prescription verification.
FDA Warning on Benzocaine Use 
FDA has issued a warning to consumers and health care providers 
regarding the use of benzocaine and its association with a rare, but seri-
ous condition, methemoglobinemia. FDA also stresses that benzocaine 
products should not be used on children less than two (2) years of age, 
except under the advise of a health care provider. Methemoglobinemia 
results in the amount of oxygen carried through the bloodstream be-
ing greatly reduced, and in the most severe cases, can result in death. 
Benzocaine gels and liquids are sold over-the-counter under different 
brand names – such as Anbesol®, Hurricaine®, Orajel®, Baby Orajel, 
Orabase®, and store brands – and are used to relieve pain from a variety 
of conditions including teething, canker sores, and irritation of the mouth 
and gums. Benzocaine is also sold in other forms such as lozenges and 
spray solutions. 
FDA notes that methemoglobinemia has been reported with all 
strengths of benzocaine gels and liquids, including concentrations as low 
as 7.5%. Further, the cases occurred mainly in children aged two years or 
younger who were treated with benzocaine gel for teething. Symptoms 
include pale, gray, or blue colored skin, lips, and nail beds; shortness of 
breath; fatigue; confusion; headache; lightheadedness; and rapid heart 
rate and usually appear within minutes to hours of applying benzocaine. 
Symptoms may occur with the first application of benzocaine or after 
additional use. FDA advises that if consumers or their children experi-
ence any of these symptoms after taking benzocaine, they should seek 
medical attention immediately. The FDA safety warning is available at 
www.fda.gov.
FDA Reminder About Pradaxa Storage/Handling
FDA issued a safety alert regarding special handling instructions for 
Pradaxa® due to concerns that these requirements are not commonly 
known. FDA advises that Pradaxa, an anticoagulant medication known 
as a direct thrombin inhibitor, should only be dispensed and stored in 
the original bottle or blister package due to the potential for product 
breakdown from moisture and loss of potency. 
Specifically, FDA advises pharmacists that Pradaxa should only be 
dispensed in the original manufacturer bottle with the original dessicant 
cap. Pradaxa should not be repackaged. Patients should be advised to 
store the medication in the original container and avoid using pill boxes 
or other containers for storage. Also, once a bottle is opened, the product 
must be used within 30 days to ensure potency. The Pradaxa label and 
medication guide contain more information about these storage and 
handling requirements. The FDA safety alert is available on the FDA 
Web site at www.fda.gov.
Board Members Retire  
Board members Vern Ben-
jamin, RPh, of Argyle, IA, 
and Ann Diehl, ARNP, of 
Osceola, IA, retired from 
the Board on April 30, 2011. 
Vern served nine years on 
the Board, beginning May 1, 
2002, and was chairperson of 
the Board from May 1, 2009, 
until his retirement. Ann, a retired nurse practitioner, served on 
the Board three years, beginning May 1, 2008. Vern and Ann 
were instrumental in helping the Board establish the prescrip-
tion monitoring program (PMP). They also worked tirelessly to 
assist the Board in achieving its mission to protect the public. 
The Board thanks Vern and Ann for their dedicated service to 
the public and to the profession of pharmacy.
New Board Members 
Congratulations to pharmacist 
James A. Miller, RPh, of Dubuque, 
IA, who was appointed to a three-year 
term on the Iowa Board of Pharmacy 
by Governor Terry Branstad effective 
May 1, 2011. Jim is the president of 
Mercy Family Pharmacy in Dubuque, 
IA. He is a pharmacy graduate of the 
University of Iowa College of Phar-
macy and also has a master’s degree in 
business administration. Jim replaces 
Vern Benjamin. The Board welcomes Jim and looks forward 
to working with him.
Congratulations to LaDonna 
Mae Gratias of Clive, IA, who was 
appointed to a three-year term as a 
public member on the Iowa Board 
of Pharmacy by Governor Branstad 
effective May 1, 2011. LaDonna is 
a home builder and is the owner of 
Gratias Construction, Inc, of Clive, 
IA. LaDonna replaces Ann Diehl. 
The Board welcomes LaDonna and 
looks forward to working with her.
Board Member Reappointed
Congratulations to pharmacist Edward Maier, RPh, of 
Mapleton, IA, who was reappointed to a three-year term on 
the Iowa Board of Pharmacy by Governor Branstad effective 
May 1, 2011. Ed has served on the Board since 2008, when he 
was appointed by Governor Chet Culver.
Board Officers Elected
Susan Frey, RPh, of Villisca, IA, has been elected Board 
chairperson for the term May 1, 2011, to April 30, 2012. Ed 
Maier, has been elected Board vice chairperson for the same 
term.
Board Rules Committee Appointed
Board Chairperson Sue Frey has appointed the following 
Board members to the Board’s rules committee for the 2011-
2012 term: DeeAnn Wedemeyer-Oleson, PharmD, RPh,  Ed 
Maier, RPh, and Mark Anliker, RPh. The rules committee 
meets regularly to review the Board’s administrative rules and 
recommend revisions that are needed due to new developments 
in pharmacy practice and the health care delivery system.
New Board Compliance Officer  
Curtis Gerhold, RPh, of At-
kins, IA, began employment with 
the Board as a compliance officer 
on January 21, 2011. Curt has been 
a pharmacist since 1986. He is a 
graduate of the University of Iowa 
College of Pharmacy. Curt was born 
and raised in the Cedar Rapids area. 
He worked in various retail pharma-
cies from 1986 to 1999, and then in 
long-term care pharmacy from 1999 
to 2011. Curt’s territory includes the following Iowa counties: 
Benton, Butler, Cerro Gordo, Davis, Grundy, Jasper, Lucas, Ma-
haska, Marion, Marshall, Monroe, Poweshiek, Tama, Wapello, 
Wayne, and Worth. In addition to these counties, Curt shares 
the city of Cedar Rapids with compliance officer Bernard 
Berntsen, RPh,  and covers everything outside Cedar Rapids in 
Linn County. Curt receives e-mail at curtis.gerhold@iowa.gov. 
Electronic Prescriptions – Requirements 
for Transmitting Agents
The Board office and the Board’s compliance officers 
regularly receive questions regarding what is required when 
a prescriber utilizes an agent to communicate a new or refill 
prescription order to a pharmacy. To clarify this matter for all 
concerned, the Board’s rule is provided below, with require-
ments for transmitting agents highlighted.
657—IAC 8.19  Manner of issuance of a prescription 
drug or medication order. A prescription drug order or 
medication order may be transmitted from a prescriber to 
a pharmacy in written form, orally including telephone 
voice communication, or by electronic transmission in ac-
cordance with applicable federal and state laws and rules. 
Any prescription drug order or medication order provided 
to a patient in written or printed form shall include the 
original, handwritten signature of the prescriber except 
as provided in rule 657—21.7.
8.19(1) Verification. The pharmacist shall exercise pro-
fessional judgment regarding the accuracy, validity, and 
authenticity of any prescription drug order or medication 
order consistent with federal and state laws and rules. In 
exercising professional judgment, the prescribing practi-
tioner and the pharmacist shall take adequate measures 
to guard against the diversion of prescription drugs and 
controlled substances through prescription forgeries.
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8.19(2) Transmitting agent. The prescribing practitioner 
may authorize an agent to transmit to the pharmacy a 
prescription drug order or medication order orally or by 
electronic transmission provided that the name of the 
transmitting agent is included in the order.
a. New order. A new written or electronically prepared and 
transmitted prescription drug or medication order shall 
be manually or electronically signed by the prescriber. If 
transmitted by the prescriber’s agent, the name and title 
of the transmitting agent shall be included in the order 
[emphasis added].
b. Refill order or renewal order. An authorization to refill 
a prescription drug or medication order, or to renew or 
continue an existing drug therapy, may be transmitted 
to a pharmacist through oral communication, in writing, 
or by electronic transmission initiated by or directed by 
the prescriber.
(1) If the transmission is completed by the prescriber’s 
agent and the name and title of the transmitting agent 
is included in the order, the prescriber’s signature is not 
required on the fax or alternate electronic transmission 
[emphasis added].
(2) If the order differs in any manner from the original 
order, such as a change of the drug strength, dosage form, 
or directions for use, the prescriber shall sign the order as 
provided by paragraph “a.”
The Board is currently proposing to change the existing rule 
to clarify the requirement that the first and last name of the 
transmitting agent be included on all prescriptions transmitted 
to the pharmacy by a prescriber’s agent.
Update on e-Prescribing of Controlled 
Substances
The Board has proposed the following administrative rule 
regarding the electronic prescribing of controlled substances:
657 IAC—21.7(1) Controlled substances. A prescrip-
tion for a controlled substance prepared pursuant to this 
rule may be transmitted to a pharmacy via facsimile 
transmission as provided by rule 21.9(124,155A) or rules 
21.12(124,155A) through 21.16(124,155A). The transmit-
ted prescription shall include the prescriber’s original 
signature or electronic signature. A prescription for a 
controlled substance may be transmitted by a prescriber 
to a pharmacy via electronic transmission pursuant to 
DEA [Drug Enforcement Administration] requirements 
for electronic prescribing of controlled substances 
[emphasis added]. Both the prescriber’s electronic pre-
scription application and the pharmacy prescription ap-
plication shall be certified compliant with DEA regulations 
for electronic prescriptions. An electronically prepared 
prescription shall not be electronically transmitted to the 
pharmacy if the prescription has been printed prior to the 
electronic transmission. An electronically prepared and 
electronically transmitted prescription that is printed fol-
lowing the electronic transmission shall be clearly labeled 
as a copy only, not valid for dispensing.
Please watch the Board’s Web site for further information 
regarding the adoption of this rule and its eventual effective 
date. Please visit DEA’s Web site to learn more about DEA 
requirements for electronic prescriptions for controlled sub-
stances: www.deadiversion.usdoj.gov/pubs/manuals/pharm2/
pharm_content.htm. 
Iowa Prescription Monitoring Program 
Update
The PMP is proving to be a very successful health care tool 
for prescribers and pharmacists in Iowa. As of June 27, 2011, 
2,597 prescribers and 1,108 pharmacists have registered to use 
the program. The number of data queries by prescribers grew 
by 164% between 2009 and 2010, from 16,806 queries in 2009 
to 44,442 in 2010. The number of queries by pharmacists grew 
by 40% during the same time period, from 5,703 queries in 
2009 to 7,988 in 2010. The PMP is showing significant increases 
in the use of controlled substances in Iowa. Since January 1, 
2008, the number of patients receiving Schedule II medica-
tions increased from 182,755 to 297,424 (a 63% increase). The 
number of total prescriptions for controlled substances grew 
by 9.4% between 2008 and 2010. The number of total doses of 
controlled substances dispensed grew by 8.6% during the same 
time period. This mirrors the 8.8% increase seen in the number 
of prescriptions issued for hydrocodone from 2008 to 2010. The 
program is successfully reducing the incidence of patients who 
utilize multiple pharmacies and multiple prescribers to obtain 
controlled substances. The number of patients who received 
controlled substances from five or more prescribers or phar-
macies decreased by 39% between 2009 and 2010, from 3,293 
incidents to 2,016. This downward trend is continuing in 2011. 
Top 10 Controlled Substances in Iowa by 
Number of Prescriptions: January 1, 2011 to 
June 27, 2011
Controlled 
Substance
No. of 
Prescriptions
Doses 
Dispensed
Approx.
Doses/Rx
Hydrocodone 577,040 34,389,850 60
Alprazolam 202,094 2,549,245 15
Zolpidem 186,481 5,510,431 30
Oxycodone 143,645 11,144,849 80
Lorazepam 135,752 7,210,854 50
Clonzepam 122,545 7,182,716 60
Methylphenidate 113,202 5,691,021 50
Amphetamine 112,129 5,423,003 50
Codeine 64,802 3,704,192 60
Phentermine 37,753 11,183,387 300
Please note that the ranking of the top 10 controlled sub-
stances in Iowa during the first half of 2011 is different if ranked 
by the number of doses dispensed. Under that ranking, the drug 
phentermine is No. 2. This is the first time that phentermine 
has made the “top 10” since the PMP program began collecting 
data retroactive to January 1, 2008.
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During the 2011 legislative session, Iowa law was amended 
to remove the sunset provision, which would have ended the 
program on June 30, 2011. The law was also changed to allow 
authorized agents of prescribers and pharmacists to register to 
access data in the PMP when authorized by Board administra-
tive rules. This change will not take effect until approximately 
January 1, 2012, after rules are adopted by the Board.
The Iowa Board of Medicine adopted a new rule effective 
June 3, 2011, which encourages physicians to use the PMP 
database when treating chronic pain patients with controlled 
substances, if the physician believes the patient is at risk of drug 
abuse or diversion. The rule is codified at 653 IAC—13.2(7).
Fifty-Year Pharmacists
The Board congratulates the following 23 Iowa pharma-
cists who were originally licensed in 1961, have continuously 
maintained their Iowa pharmacist license, and have devoted a 
half-century of service to the public and the profession:
John Biller ..................................................LaCrescent, MN
Ellene Deets ................................................Orange City, IA
Ronald Dorris ..................................................Edmond, OK
Loren Eitreim ............................................... Evergreen, CO
Thomas Flack ........................................................Ames, IA
Gary Ford ....................................................Des Moines, IA
Melvin Galbraith .......................................Arnolds Park, IA
Jim Hopkins .......................................................LeMars, IA
Alan Harris ....................................................... Phoenix, AZ
Sylvia McCalla .................................................Billings, MT
Larry McGonigal............................................... Dexter, MO
Edwin McLuen ................................................ Indianola, IA
James Obrecht .......................................................Ames, IA
Ronald Poublon ................................................Sun City, FL
Robert Richeson ............................................ Camanche, IA
James Spratt .......................................West Des Moines, IA
Larry Sharpe .................................................. Bettendorf, IA
Richard Thomsen .............................................. Waverly, IA
Donald Unash ............................................Cedar Rapids, IA
Lucien VanElsen...........................................Brookfield, WI
Jan Wenger ................................................Cedar Rapids, IA
Dennis Ward ................................................Des Moines, IA
Richard Watkins ....................................... Independence, IA
Board Meeting Calendar
The following meeting dates have been set for future Board 
meetings:
 ♦ September 13-14, 2011, in Des Moines
 ♦ November 9-10, 2011, in Iowa City
Meeting agendas will be posted on the Board’s Web site. 
Dates are subject to change. Please check with the Board office 
at 515/281-5944 to confirm. 
Board Web site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
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